First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743

In the phase III CheckMate 743 study (NCT02899299), first-line nivolumab plus ipilimumab significantly improved overall survival (OS) versus chemotherapy in patients with unresectable malignant pleural mesothelioma (MPM). We report updated data with 3-year minimum follow-up. Adults with previously u...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of Oncology 2022-05, Vol.33 (5), p.488-499
Hauptverfasser:	Peters, S., Scherpereel, A., Cornelissen, R., Oulkhouir, Y., Greillier, L., Kaplan, M.A., Talbot, T., Monnet, I., Hiret, S., Baas, P., Nowak, A.K., Fujimoto, N., Tsao, A.S., Mansfield, A.S., Popat, S., Zhang, X., Hu, N., Balli, D., Spires, T., Zalcman, G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antineoplastic Combined Chemotherapy Protocols - adverse effects CTLA-4 dual immunotherapy first-line Humans immune checkpoint inhibitors Ipilimumab - adverse effects Life Sciences Mesothelioma, Malignant Nivolumab - therapeutic use overall survival PD-L1 Progression-Free Survival
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!